Výsledky vyhledávání - "Bryan J Little"

Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era

Autor: Bijal D. Shah, Bryan J Little, Samir Dalia, Lubomir Sokol, Ji-Hyun Lee, Julio C. Chavez, Kate Fisher, Celeste M. Bello, Paul A. Chervenick, Eduardo M. Sotomayor

Publikováno v: Annals of hematology. 93(8)

Serum albumin (SA) has been shown to be a prognostic marker in many hematological malignancies and in diffuse large B-cell lymphoma (DLBCL) prior to chemo-immunotherapy. SA may be a surrogate for age, comorbid status, and disease severity. Here, we a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::695c4046686a1884723c881e592c8b2e
https://pubmed.ncbi.nlm.nih.gov/24590536

Zobrazit plný text záznamu

A Retrospective Evaluation Of Insurance Status As It Relates To Outcomes In Diffuse Large B-Cell Lymphoma

Autor: Bryan J Little, Julio C Chavez, Celeste M. Bello, Paul Chervenick, Lubomir Sokol, Eduardo M. Sotomayor, Bijal D. Shah

Publikováno v: Blood. 122:1702-1702

Introduction Despite the advances in Diffuse Large B-Cell Lymphoma (DLBCL) treatment, there is a lack of uniformity regarding survival among the entire patient population. This study investigates several individual-level markers of socioeconomic and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a8c5e81046ccb9d191f62716d0785d7
https://doi.org/10.1182/blood.v122.21.1702.1702

Zobrazit plný text záznamu

A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prognostic Index (A-IPI)

Autor: Samir Dalia, Julio C Chavez, Celeste M. Bello, Paul A. Chervenick, Bryan J Little, Najla H Al Ali, Lubomir Sokol, Eduardo M. Sotomayor, Ji-Hyun Lee, Kate Fisher, Zachary Thompson, Bong-jin Choi, Bijal D. Shah

Publikováno v: Blood. 122:4267-4267

Introduction Low serum albumin (SA) has been identified as a prognostic marker in multiple hematological malignancies including diffuse large B-cell lymphoma (DLBCL). Low SA may be an indicator of worsening disease biology, increased inflammation, or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4922bc7d589f9d4cbc5c8258b3f347eb
https://doi.org/10.1182/blood.v122.21.4267.4267

Zobrazit plný text záznamu

Cytarabine Either with Induction or Conditioning May Improve Outcomes Among Those Undergoing Autologous Transplantation in First or Second Remission for Mantle Cell Lymphoma

Autor: Lubomir Sokol, Marcie Tomblyn, Bijal D. Shah, Ernesto Ayala, Eduardo M. Sotomayor, Jennifer L. Cultrera, Bryan J Little, Celeste M. Bello

Publikováno v: Blood. 120:4546-4546

Abstract 4546 Introduction: Consolidation with autologous transplantation (AutoSCT) may extend progression free survival when administered following initial induction. Published data suggest intensive cytarabine containing induction may improve outco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::befcd09b346c8c07f788d1620d38f0d4
https://doi.org/10.1182/blood.v120.21.4546.4546

Zobrazit plný text záznamu

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure

Autor: Javier Pinilla-Ibarz, Alan F. List, Jeffrey E. Lancet, Rami S. Komrokji, Asmita Mishra, Bryan J Little, Viet Q. Ho, Eric Padron, Najla Al Ali

Publikováno v: Blood. 120:2815-2815

2815 [][1] Background: Azacitidine has emerged as the standard of care for treatment of higher risk MDS based upon results of the AZA-001 study. Several groups reported poor outcomes after AZA failure in patients with int-2 or high risk International

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc108fdcc56f5cc6ab6f85f5956b4cd2
https://doi.org/10.1182/blood.v120.21.2815.2815

Zobrazit plný text záznamu

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Autor: Rami S. Komrokji, Bryan J Little, Pearlie K. Epling-Burnette, Asmita Mishra, Maria Corrales-Yepez, Javier Pinilla-Ibarz, Najla Al Ali, Eric Padron, Alan F. List, Jeffrey E. Lancet, Ling Zhang

Publikováno v: Blood. 120:3852-3852

Abstract 3852 Background: Azanucleosides (AZN) and allogeneic stem cell transplantation (ASCT) are the only disease altering treatment modalities for patients with myelodysplastic syndrome (MDS). Azacitidine (AZA) demonstrated an overall survival (OS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bfa360b0c5cfa525f0601828b8ee958d
https://doi.org/10.1182/blood.v120.21.3852.3852

Zobrazit plný text záznamu

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications

Autor: Mohamed A. Kharfan-Dabaja, Najla Al Ali, Alan F. List, Ling Zhang, Asmita Mishra, Jeffrey E. Lancet, Maria Corrales-Yepez, Rami S. Komrokji, Eric Padron, Bryan J Little, Pearlie K. Epling-Burnette, Javier Pinilla-Ibarz

Publikováno v: Blood. 120:2816-2816

Abstract 2816 Background: The International Prognostic Scoring System (IPSS) was recently revised under the auspices of MDS foundation as a collaborative international effort. The proposed R-IPSS is suggested to refine the prognostic value of the IPS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c56b8288556e34fd6ff6f471a1edfbbe
https://doi.org/10.1182/blood.v120.21.2816.2816

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání